Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Kyverna Therapeutics, Inc. and keeping the price target at $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors that highlight the promising potential of Kyverna Therapeutics’ KYV-101. The company has presented encouraging long-term data for KYV-101, demonstrating durable, drug-free, and disease-free remission in patients with myasthenia gravis (MG) and stiff person syndrome (SPS). This suggests that KYV-101 could significantly alter the treatment landscape for these conditions.
Furthermore, the innovative design of the Phase 3 trial in MG, which is well-powered for demonstrating superiority with a relatively small sample size, provides a clear and expedited path to regulatory approval. The commercial strategy also supports a swift and efficient market launch, with SPS offering a potentially larger market opportunity than initially anticipated. These factors collectively underpin Ulz’s positive outlook and Buy rating for Kyverna Therapeutics.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.